Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentane-1,5-diol is a small molecule aliphatic diol developed by Ambria Dermatology as a topical hydrogel formulation for the treatment of impetigo. It functions as a direct antimicrobial agent with activity against both sensitive and multi-resistant aerobic bacteria, demonstrating minimum inhibitory concentrations (MIC) between 5% and 12.5%. While its exact mechanism of action is not fully understood, it is hypothesized to inhibit bacterial growth by withdrawing water from bacterial cells. In addition to its therapeutic properties, pentane-1,5-diol acts as a percutaneous absorption enhancer and a preservative in topical formulations. It is characterized by low toxicity, low risk of skin and eye irritation, and a lack of odor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentane-1,5-diol.